Dermatitis, Atopic
Conditions
Brief summary
To assess the pharmacokinetics of 3 doses and the food effect of a single high dose of BBI-5000 capsules in healthy adult subjects.
Detailed description
This is an open-label, randomized, 4-period, 4-way crossover, 4-sequence study to evaluate the pharmacokinetics (PK) and food effect of BBI-5000 capsules in healthy adult subjects. Participating subjects will receive a single oral dose of BBI-5000 followed by a washout period of 7-14 days between doses. The treatment period will be followed by 5-10 day follow-up period. PK and PD will be assessed by blood sampling through 72 hours postdose. Safety will be assessed through collection of vital signs, adverse events, physical examination, ECGs and clinical laboratory tests.
Interventions
DRUGBBI-5000
BBI-5000 low dose, middle dose, or high doses
Sponsors
Fresh Tracks Therapeutics, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Non-smoker * Medically healthy * 32.0 \>= BMI \>= 18.5 kg/m\^2 * Weight \>= 50 kg for males * Weight \>= 45 kg for females * For a female of childbearing potential: either be sexually inactive for 14 days prior to the first dose and throughout the study or be using an acceptable birth control method as dictated by the study * Willing to comply with protocol and understands study procedures outlined in the ICF
Exclusion criteria
* Subject is mentally or legally incapacitated or has significant emotional problems * History or presence of medical or psychiatric disease * History of any illness that might confound the results of the study * History or presence of alcoholism or drug abuse * History or presence of hypersensitivity or idiosyncratic reaction the the study drug excipient * History or presence of lactose intolerance * Pregnant or lactating females * Seated blood pressure less than 90/40 mmHg or greater than 140/90 mmHg * Seated heart rate lower than 40 bpm or higher than 99 bpm * Unable to refrain from or anticipates the use of any drug * Diet incompatible with the on-study diet * Donation of blood or significant blood loss within 56 days prior to the first study dose * Participation in another clinical trial within 28 days prior to the first study dose
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Half-life for BBI-5000 and the 3 metabolites | Week 4 |
| Terminal plasma elimination rate constant for BBI-5000 and the 3 metabolites | Week 4 |
| BBI-5000 concentrations in plasma after dosing in fed and fasted conditions | Week 4 |
| Plasma concentrations after single dosing of BBI-5000 for BBI-5000 and 3 metabolites | Week 4 |
| Area Under Curve (AUC) for BBI-5000 and 3 metabolites | Week 4 |
| Maximum Plasma Concentration (Cmax) for BBI-5000 and 3 metabolites | Week 4 |
| Time of Occurrence of Cmax (Tmax) | Week 4 |
| Clearance (CL/F) | Week 4 |
Secondary
| Measure | Time frame |
|---|---|
| Safety and tolerability as measured by assessment of treatment-related adverse events, safety laboratory, vital signs, electrocardiogram and physical examination results | Week 4 |
Other
| Measure | Time frame |
|---|---|
| Eosinophil shape change in whole blood as measured by dose and exposure-related dependent changes over time | Week 4 |
Countries
United States
Outcome results
None listed